Moreover, depletion of TAMs or CD8+ T cells in the presence of DMXAA significantly reduced the anti-tumor activity of the combination therapy, confirming the contributions of these immune cells to the therapeutic efficacy (Supplementary Fig. 5a). Here, CD8A is linked to neoplasm.